Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company symbols : MRTX save search
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | News | $3.875 2.51% 0.65% 6K
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Published: 2024-01-23 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $92.09 1.58% 0.01% 7.3M
|
Finance
|
| O: -0.07%
H: 1.38%
C: 1.25%
EVR | $192.08 3.07% 0.0% 380K
|
Finance
|
| O: 0.35%
H: 0.29%
C: -0.26%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: 0.89%
acquisition
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics financial results
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.9%
H: 1.08%
C: 0.61%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.2%
H: 0.43%
C: -0.38%
KURA | News | $18.22 3.94% 3.79% 2M
|
Health Technology
|
| O: 0.13%
H: 6.0%
C: 5.25%
ko-2806 collaboration therapeutics agreement
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News 0 d | $92.09 1.58% 0.01% 7.3M
|
Finance
|
| O: 0.83%
H: 0.0%
C: 0.0%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | News | $3.875 2.51% 0.65% 6K
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Published: 2023-05-24 (Crawled : 20:00) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.81%
H: 0.32%
C: -0.59%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -6.18%
H: 0.0%
C: -6.64%
opdivo update sapphire therapeutics study
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
Published: 2022-12-02 (Crawled : 13:20) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.63%
H: 0.98%
C: 0.95%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -1.42%
H: 7.07%
C: 6.71%
sapphire therapeutics update study
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
Published: 2021-12-10 (Crawled : 19:00) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
| Email alert
Add to watchlist
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
| Email alert
Add to watchlist
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
| Email alert
Add to watchlist
MRK | $126.94 0.92% 0.0% 7.8M
|
Health Technology
| Email alert
Add to watchlist
artificial intelligence drug cancer drug cancer
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.